W
WAVEMAN · COMPANY
ZIVO · Zivo Bioscience, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

ZIVO

Zivo Bioscience, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001101026
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$200.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
+468.6%
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$200.0K over 180 days
+$200.0K of it by a 10%+ holder
more than 79% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
+468.6% year over year
more than 93% of Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -79.4%
-79.4%12M
-93%-62%-31%+0%2025-092025-102025-122026-032026-052026-072026-09 2025-10-08 · Maggiore Christopher D. bought $284.4K2025-10-13 · STROME INVESTMENT MANAGEMENT LP bought $250.0K2025-09-30 · YALDOO LAITH L bought $245.0K2026-04-17 · STROME INVESTMENT MANAGEMENT LP bought $200.0K2026-02-12 · STROME GROUP, INC. bought $195.4K2026-01-26 · Cornell Alison A bought $100.0K2026-01-26 · PAYNE JOHN BERNARD bought $100.0K2026-02-10 · YALDOO LAITH L bought $25.0K2025-11-28 · YALDOO LAITH L bought $25.0K2025-10-10 · YALDOO LAITH L bought $20.0K2026-02-27 · YALDOO LAITH L bought $15.0K2026-01-14 · Maggiore Christopher D. bought $15.0K2026-01-14 · YALDOO LAITH L bought $15.0K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $200.0K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Zivo Bioscience, Inc. insiders bought a net $200.0K of stock across 42 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
STROME INVESTMENT MANAGEMENT LP
—
BUY
2026-04-17
100,000.0
$200.0K
YALDOO LAITH L
Director
BUY
2026-02-27
1,543.0
$15.0K
STROME GROUP, INC.
—
BUY
2026-02-12
20,000.0
$195.4K
YALDOO LAITH L
Director
BUY
2026-02-10
2,434.0
$25.0K
Cornell Alison A
Director
BUY
2026-01-26
11,709.0
$100.0K
42 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 37 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
CoreCap Advisors, LLC
4,360.0 sh
$17.6K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2024-122023-122022-122021-12
REVENUE$157.2K$27.6K$0$0
GROSS PROFIT$49.0K$11.6K$0—
OPERATING INCOME$-13.4M$-7.3M$-8.7M$-8.6M
NET INCOME$-13.4M$-7.8M$-8.7M$-8.8M
EPS (DILUTED)-4.23-4.60——
OPERATING CASH FLOW$-4.3M$-5.8M$-7.1M$-6.8M
CASH——$1.8M$8.9M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →